HU0203438A3 - 5-(2-substituted-5-heterocyclysulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors, process for their preparation and pharmaceutical compositions containing them - Google Patents

5-(2-substituted-5-heterocyclysulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HU0203438A3
HU0203438A3 HU0203438A HU0203438A HU0203438A3 HU 0203438 A3 HU0203438 A3 HU 0203438A3 HU 0203438 A HU0203438 A HU 0203438A HU 0203438 A HU0203438 A HU 0203438A HU 0203438 A3 HU0203438 A3 HU 0203438A3
Authority
HU
Hungary
Prior art keywords
heterocyclysulphonylpyrid
dihydropyrazolo
pyrimidin
yl
ones
Prior art date
Application number
HU0203438A
Other versions
HU0203438A2 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9924041.8A priority Critical patent/GB9924041D0/en
Priority to GB0018660A priority patent/GB0018660D0/en
Application filed by Pfizer filed Critical Pfizer
Priority to PCT/IB2000/001430 priority patent/WO2001027112A1/en
Publication of HU0203438A2 publication Critical patent/HU0203438A2/en
Publication of HU0203438A3 publication Critical patent/HU0203438A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
HU0203438A 1999-10-11 2000-10-04 5-(2-substituted-5-heterocyclysulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors, process for their preparation and pharmaceutical compositions containing them HU0203438A3 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9924041.8A GB9924041D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds
GB0018660A GB0018660D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
PCT/IB2000/001430 WO2001027112A1 (en) 1999-10-11 2000-10-04 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
HU0203438A2 HU0203438A2 (en) 2003-01-28
HU0203438A3 true HU0203438A3 (en) 2003-05-28

Family

ID=26244758

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203438A HU0203438A3 (en) 1999-10-11 2000-10-04 5-(2-substituted-5-heterocyclysulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors, process for their preparation and pharmaceutical compositions containing them

Country Status (32)

Country Link
US (1) US6756373B1 (en)
EP (1) EP1222190A1 (en)
JP (1) JP2003511452A (en)
CN (1) CN1378547A (en)
AP (1) AP200202455A0 (en)
AR (1) AR022665A1 (en)
AU (1) AU7547900A (en)
BG (1) BG106568A (en)
BR (1) BR0014695A (en)
CA (1) CA2387353A1 (en)
CO (1) CO5261539A1 (en)
CZ (1) CZ20021151A3 (en)
DZ (1) DZ3218A1 (en)
EA (1) EA200200240A1 (en)
EE (1) EE200200192A (en)
GT (1) GT200000168A (en)
HU (1) HU0203438A3 (en)
IL (1) IL149025D0 (en)
IS (1) IS6288A (en)
MA (1) MA26824A1 (en)
NO (1) NO20021695L (en)
NZ (1) NZ517324A (en)
OA (1) OA12058A (en)
PA (1) PA8504401A1 (en)
PE (1) PE07362001A1 (en)
PL (1) PL357522A1 (en)
SK (1) SK4562002A3 (en)
SV (1) SV2002000192A (en)
TN (1) TNSN00198A1 (en)
TR (1) TR200200954T2 (en)
UY (1) UY26383A1 (en)
WO (1) WO2001027112A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CN1655820A (en) * 2002-05-23 2005-08-17 辉瑞大药厂 Pharmaceutical combination of PDE5 inhibitors with ace inhibitors
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
JP4208512B2 (en) 2002-07-23 2009-01-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for producing 5- (2'-pyridyl) -2-pyridone derivative
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
NZ542097A (en) 2003-04-29 2008-12-24 Pfizer Ltd 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
JP2006219373A (en) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pyridinylpyrazolopyrimidinone derivative having pde 7 inhibition
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (en) 2004-01-22 2007-07-03 Pfizer triazole derivatives which inhibit vasopressin antagonist activity
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2005089766A1 (en) * 2004-03-05 2005-09-29 Altana Pharma Ag Novel use for pde5 inhibitors
EP1742950B1 (en) 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
DE602006003416D1 (en) 2005-03-21 2008-12-11 Pfizer Ltd Substituted triazole derivatives as oxytocin
AU2006245416B2 (en) 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
JP5084725B2 (en) 2005-06-06 2012-11-28 武田薬品工業株式会社 Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Organic compounds for treating reduced dopamine receptor signalling activity
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
US20080318982A1 (en) * 2005-12-20 2008-12-25 Pfizer, Inc. Pharmaceutical Combination for the Treatment of Luts
MX2008015489A (en) * 2006-06-06 2009-01-13 Intra Cellular Therapies Inc Organic compounds.
WO2008044767A1 (en) * 2006-10-13 2008-04-17 Takeda Pharmaceutical Company Limited Aromatic amine derivative and use thereof
WO2008063505A1 (en) * 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
ES2310144B1 (en) * 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermediates for the preparation of an inhibitor of phosphodiesterase type 5.
US20100210668A1 (en) * 2007-10-02 2010-08-19 Dong-A Pharm. Co., Ltd. Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
US8846693B2 (en) * 2007-12-06 2014-09-30 Intra-Cellular Therapies, Inc. Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones
PT2240490E (en) 2007-12-06 2013-12-09 Takeda Pharmaceutical Organic compounds
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
BRPI0922700A2 (en) 2008-12-06 2015-08-11 Intracellular Therapies Inc Organic compounds
BRPI0922351A2 (en) 2008-12-06 2018-06-05 Intracellular Therapies Inc organic compounds
MX2011005935A (en) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Organic compounds.
PE09952011A1 (en) * 2008-12-06 2012-02-06 Intra Cellular Therapies Inc Pyrrolo [3,4-e] pyrimidine as inhibitors of PDE1
AU2009322901A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP5989993B2 (en) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc Organic compounds
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
JP5879336B2 (en) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
JP6549040B2 (en) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New use
EP3479825A1 (en) 2013-03-15 2019-05-08 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders
CN105377846B (en) 2013-03-15 2018-03-20 细胞内治疗公司 Organic compounds
JP2017502059A (en) 2014-01-08 2017-01-19 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Formulations and pharmaceutical compositions
DK3157926T3 (en) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
CA2961212A1 (en) 2014-09-17 2016-03-24 Intra-Cellular Therapies, Inc. Compounds and methods
JP2017536410A (en) 2014-12-06 2017-12-07 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
KR20170089001A (en) 2014-12-06 2017-08-02 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1996005176A1 (en) 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JP3713783B2 (en) 1995-01-20 2005-11-09 大正製薬株式会社 1H- pyrazolo [3,4-d] pyrimidin-4-one derivative
NZ303886A (en) 1995-03-10 1998-11-25 Sanofi Winthrop Inc 1-cyclopentyl (or tert butyl)-6-aryl (or heteroaryl)-pyrazolo[3,4-d]pyrimidin-4-one derivatives and medicaments
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
SI9500173B (en) 1995-05-19 2002-02-28 Lek, Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
AU706628B2 (en) 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
EA004315B1 (en) 1997-04-25 2004-02-26 Пфайзер Инк. New sulfonilbenzoynye acid and a process for preparing 4-benzamidopirazolo-5-carboxamides from their use
GT199800127A (en) 1997-08-29 2000-02-01 therapeutic combinations.
ES2242124T3 (en) * 1998-04-20 2005-11-01 Pfizer Inc. Acid derivatives pyridin-3-carboxylic acid and their use as intermediates.
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
AT250063T (en) 1998-10-23 2003-10-15 Pfizer Pyrazolopyrimidinones, cgmp PDE5 inhibitors, for the treatment of sexual dysfunctions
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc Compositions and methods for treating conditions responsive to testosterone elevation
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20020173502A1 (en) * 2001-03-09 2002-11-21 Allerton Charlotte Moira Norfor Pharmaceutically active compounds
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
WO2003012095A1 (en) 2001-07-28 2003-02-13 Midwest Research Institute Thermal tolerant exoglucanase from acidothermus cellulolyticus

Also Published As

Publication number Publication date
IS6288A (en) 2002-02-26
CO5261539A1 (en) 2003-03-31
HU0203438A2 (en) 2003-01-28
AR022665A1 (en) 2002-09-04
SV2002000192A (en) 2002-07-16
TR200200954T2 (en) 2002-09-23
BG106568A (en) 2002-12-29
CZ20021151A3 (en) 2003-03-12
SK4562002A3 (en) 2003-04-01
WO2001027112A1 (en) 2001-04-19
PE07362001A1 (en) 2001-07-19
EP1222190A1 (en) 2002-07-17
GT200000168A (en) 2002-04-03
BR0014695A (en) 2002-06-18
CN1378547A (en) 2002-11-06
UY26383A1 (en) 2001-05-31
CA2387353A1 (en) 2001-04-19
PA8504401A1 (en) 2002-04-25
PL357522A1 (en) 2004-07-26
TNSN00198A1 (en) 2002-05-30
NO20021695L (en) 2002-06-07
DZ3218A1 (en) 2001-04-19
AP200202455A0 (en) 2002-06-30
NZ517324A (en) 2003-09-26
IL149025D0 (en) 2002-11-10
OA12058A (en) 2006-05-03
EA200200240A1 (en) 2002-10-31
EE200200192A (en) 2003-06-16
MA26824A1 (en) 2004-12-20
NO20021695D0 (en) 2002-04-10
AU7547900A (en) 2001-04-23
US6756373B1 (en) 2004-06-29
JP2003511452A (en) 2003-03-25

Similar Documents

Publication Publication Date Title
IL128994A (en) Quinoline and naphthyridine derivatives and salts thereof, processes for their preparation, pharmaceutical compositions containing them and use thereof as medicaments
HU0100394A3 (en) 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
MXPA98008897A (en) Pyrazolo[4,3-d]pyrimidine derivatives and pharmaceutical compositions containing them.
HU0203509A3 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
SI1266899T1 (en) Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them
HU0301651A3 (en) Indolylmaleimide derivatives, pharmaceutical compositions containing them, process for producing them and their use
PT1614683E (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
HU0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HRP20000153A2 (en) Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
HU0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HK1043591A1 (en) Substituted 2-aryl-3-(heteroaryl)-imidazo Ä1,2-alphaÜpyrimidines, and related pharmaceutical compositions and methods
IL122464A (en) N-pyrazine-pyridinesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
HU0001562A3 (en) Aminotriazole derivatives process for their preparation and medicaments containing the same
IL150883A (en) Pyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
ZA200401316B (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.
IL144626A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
HU9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
HU0303391A3 (en) Aliphatic nitrogenous five-membered ring compounds, process for their preparation, pharmaceutical compositions containing them and their use
AU2001287654A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HU0103333A3 (en) Pyrroloindoles, pyridoindoles and azepinoindiles as 5-ht2c agonists, process for their preparation and pharmaceutical compositions containing them
HU0000562A3 (en) Fused pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
GB0330043D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
PT1150961E (en) Pirazolecarboxylic acid derivatives process for their preparation and the pharmaceutical compositions that contain them
HU9902460A3 (en) Novel substituted imidazole compounds, their use, method for their preparation and pharmaceutical compositions containing them
IL153997A (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them